Janus kinases (JAKs) are a family of proinflammatory enzymes able to mediate the immune responses and the inflammatory cascade by modulating multiple cytokine expressions as well as various growth factors. In the present study, the inhibition of the JAK-signal transducer and activator of transcription (STAT) signaling pathway is explored as a potential strategy for treating autoimmune and inflammatory disorders. A computationally driven approach aimed at identifying novel JAK inhibitors based on molecular topology, docking, and molecular dynamics simulations was carried out. For the best candidates selected, the inhibitory activity against JAK2 was evaluated in vitro. Two hit compounds with a novel chemical scaffold, 4 (IC50 = 0.81 μM) and 7 (IC50 = 0.64 μM), showed promising results when compared with the reference drug Tofacitinib (IC50 = 0.031 μM).

Galvez-Llompart M., Ocello R., Rullo L., Stamatakos S., Alessandrini I., Zanni R., et al. (2021). Targeting the JAK/STAT Pathway: A Combined Ligand- And Target-Based Approach. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 61(6), 3091-3108 [10.1021/acs.jcim.0c01468].

Targeting the JAK/STAT Pathway: A Combined Ligand- And Target-Based Approach

Ocello R.;Rullo L.;Stamatakos S.;Alessandrini I.;Cavalli A.;Candeletti S.;Masetti M.;Romualdi P.;Recanatini M.
2021

Abstract

Janus kinases (JAKs) are a family of proinflammatory enzymes able to mediate the immune responses and the inflammatory cascade by modulating multiple cytokine expressions as well as various growth factors. In the present study, the inhibition of the JAK-signal transducer and activator of transcription (STAT) signaling pathway is explored as a potential strategy for treating autoimmune and inflammatory disorders. A computationally driven approach aimed at identifying novel JAK inhibitors based on molecular topology, docking, and molecular dynamics simulations was carried out. For the best candidates selected, the inhibitory activity against JAK2 was evaluated in vitro. Two hit compounds with a novel chemical scaffold, 4 (IC50 = 0.81 μM) and 7 (IC50 = 0.64 μM), showed promising results when compared with the reference drug Tofacitinib (IC50 = 0.031 μM).
2021
Galvez-Llompart M., Ocello R., Rullo L., Stamatakos S., Alessandrini I., Zanni R., et al. (2021). Targeting the JAK/STAT Pathway: A Combined Ligand- And Target-Based Approach. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 61(6), 3091-3108 [10.1021/acs.jcim.0c01468].
Galvez-Llompart M.; Ocello R.; Rullo L.; Stamatakos S.; Alessandrini I.; Zanni R.; Tunon I.; Cavalli A.; Candeletti S.; Masetti M.; Romualdi P.; Recan...espandi
File in questo prodotto:
File Dimensione Formato  
acs.jcim.2021_1.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 6.83 MB
Formato Adobe PDF
6.83 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/826976
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact